PHIO
- Phio Pharmaceuticals Corp.
()
Overview
Company Summary
Phio Pharmaceuticals Corp. (PHIO) is a biotechnology company that focuses on developing and commercializing novel RNA interference (RNAi) technologies. RNAi is a natural cellular process that regulates gene expression and controls the production of proteins in cells. Phio Pharmaceuticals specifically aims to harness this process for therapeutic purposes.
The company's primary focus is on developing innovative RNAi-based therapies for the treatment of various diseases, including cancer and genetic disorders. Phio's proprietary RNAi technology platform allows the selective silencing of disease-causing genes, providing potential solutions for conditions that have previously been challenging to treat.
Phio Pharmaceuticals utilizes a two-fold approach in its research and development efforts. Firstly, it employs a self-delivering RNAi (sd-rxRNA) technology to enable direct delivery of RNAi molecules into target cells without additional delivery agents. This approach simplifies the therapeutic development process by reducing the need for complex delivery systems.
Secondly, Phio incorporates immune-stimulating modulators known as immune checkpoint modulators (ICMs) to enhance the therapeutic effect of its RNAi technology. By combining RNAi with ICMs, the company aims to exert a potent and focused immune response against targeted diseases, potentially allowing for greater treatment efficiency and effectiveness.
Overall, Phio Pharmaceuticals strives to advance the understanding and application of RNAi technology in the field of medicine. Through its innovative approach and technologies, the company aims to develop groundbreaking therapies that could revolutionize the treatment options available for patients suffering from various diseases.